Internet CBT Eases Depressive Symptoms in Multiple Sclerosis Internet CBT Eases Depressive Symptoms in Multiple Sclerosis
Internet-based cognitive behavioral therapy significantly reduces depressive symptoms in patients with MS, results from a multisite, phase 3, randomized trial show.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - October 4, 2023 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche ’s Evrysdi able to sit independently after 1 year of treatment
RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of Evrysdi treatment – without treatment these babies would never be able to sitAll babies were able to swallow and feed orally and none required permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globallyBasel, 04 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi ® (risdi...
Source: Roche Media News - October 4, 2023 Category: Pharmaceuticals Source Type: news
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche ’s Evrysdi able to sit independently after 1 year of treatment
RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of Evrysdi treatment – without treatment these babies would never be able to sitAll babies were able to swallow and feed orally and none required permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globallyBasel, 04 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi ® (risdi...
Source: Roche Investor Update - October 4, 2023 Category: Pharmaceuticals Source Type: news
Time to Add aHSCT to Standard Care in RRMS? Time to Add aHSCT to Standard Care in RRMS?
73% of patients with relapsing remitting multiple sclerosis were disease free 5 years after aHSCT treatment, and more than half reported improved disability.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Media News - October 2, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
Stem Cell Transplants Effective in MS
(MedPage Today) -- Most patients with relapsing-remitting multiple sclerosis (RRMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) showed no evidence of disease activity (NEDA) for 5 to 10 years, observational data showed... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 30, 2023 Category: Neurology Source Type: news
Peer-to-Peer: Multiple Sclerosis and Your Mental Health
Two people discuss how living with relapsing-remitting multiple sclerosis impacts mental health in a peer-to-peer discussion. (Source: WebMD Health)
Source: WebMD Health - September 29, 2023 Category: Consumer Health News Source Type: news
Sociodemographic Factors Before MS Diagnosis Tied to Disease Severity
FRIDAY, Sept. 29, 2023 -- Education, income, and marital status prior to multiple sclerosis (MS) onset are associated with future symptom and disability severity, according to a study published online Sept. 26 in JAMA Network Open.
Anna He,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 29, 2023 Category: Pharmaceuticals Source Type: news
The Financial Impact of Multiple Sclerosis
In a peer-to-peer conversation, two people with relapsing-remitting multiple sclerosis discuss how they manage the costs of treatment. (Source: WebMD Health)
Source: WebMD Health - September 28, 2023 Category: Consumer Health News Source Type: news
Stem Cell Treatment Halts MS for Some Patients
WEDNESDAY, Sept. 27, 2023 -- A new study is strengthening the evidence that stem cell transplants can be highly effective for some people with multiple sclerosis -- sending the disease into remission for years, and sometimes reversing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 27, 2023 Category: General Medicine Source Type: news
Emotional Issues Could Be Early Sign of MS
WEDNESDAY, Sept. 27, 2023 -- A newer understanding of multiple sclerosis (MS) suggests that psychiatric conditions like anxiety and depression may emerge long before classic MS symptoms.“For a long time, it was thought that MS only really... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 27, 2023 Category: General Medicine Source Type: news
aHSCT Beneficial for Most Patients With Relapsing-Remitting MS
TUESDAY, Sept. 26, 2023 -- Autologous hematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS) yields freedom from disease activity for most patients, according to a study published online Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 26, 2023 Category: Pharmaceuticals Source Type: news
Fall assessment and monitoring in people with multiple sclerosis: a practical evidence-based review for clinicians - Gopal A, Gelfand JM, Bove R, Block VJ.
PURPOSE OF REVIEW: Falls occur in more than half of all people with multiple sclerosis (MS) but tend to be underdiagnosed and underreported in clinical encounters. This narrative review aims to summarize evidence-based approaches for evaluating fall risk a... (Source: SafetyLit)
Source: SafetyLit - September 25, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Intimate partner violence and multiple sclerosis - Freedman DE, Krysko KM, Feinstein A.
People with MS may be at heightened risk of intimate partner violence (IPV) compared to the general population; however, little is known about the prevalence of IPV among people with MS or its effects on MS-specific clinical outcomes. Additionally, while M... (Source: SafetyLit)
Source: SafetyLit - September 25, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
